Evolving Foundations

CAR T-Cell Therapy: Updates in Nursing Management

Brittney Baer

chimeric antigen receptor T-cell therapy, cytokine release syndrome, neurotoxicity
CJON 2021, 25(3), 255-258. DOI: 10.1188/21.CJON.255-258

Chimeric antigen receptor (CAR) T-cell therapy is an evolving treatment used for hematologic malignancies; it requires specialized nursing care and knowledge. This article discusses updates in the nursing management of CAR T-cell therapies and their use in adult patients. A comprehensive review of the literature, including peer-reviewed articles and pharmaceutical drug labels, was conducted. Oncology and intensive care unit nurses will need to be knowledgeable about and remain current in the management of patients receiving CAR T-cell therapies because they pose different challenges than seen with traditional chemotherapy regimens.


  • CAR T-cell therapies are on the rise, with nursing playing an integral role in the care of patients receiving them.
  • Nurses should know their facility’s standard operating procedures in the care of patients undergoing CAR T-cell therapy.
  • Patients receiving CAR T-cell therapies require high levels of close monitoring and vigilant nursing care during their treatment course; prompt toxicity intervention is key to improved patient outcomes.
Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.